L-223-2025
Agreement ID
L-223-2025
Lead IC
NICHD
Exclusivity
Exclusive
External Party
EnZeta Immunotherapies, Inc.
Fiscal Year
2026
Territory
Worldwide
Execution Date
Effective Date
Export Date